Eddie Hickman
Stock Analyst at Guggenheim
(3.35)
# 1,048
Out of 5,241 analysts
23
Total ratings
63.64%
Success rate
15.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZVRA Zevra Therapeutics | Maintains: Buy | $23 → $25 | $11.01 | +127.07% | 2 | May 8, 2026 | |
| ATAI AtaiBeckley | Maintains: Buy | $11 → $16 | $4.02 | +298.51% | 2 | Apr 17, 2026 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $87 → $90 | $62.48 | +44.05% | 10 | Feb 25, 2026 | |
| PMN ProMIS Neurosciences | Maintains: Buy | $125 → $35 | $10.39 | +236.86% | 4 | Feb 6, 2026 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $0.23 | - | 4 | Aug 29, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $21.39 | +49.60% | 1 | Mar 13, 2025 |
Zevra Therapeutics
May 8, 2026
Maintains: Buy
Price Target: $23 → $25
Current: $11.01
Upside: +127.07%
AtaiBeckley
Apr 17, 2026
Maintains: Buy
Price Target: $11 → $16
Current: $4.02
Upside: +298.51%
Tarsus Pharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $87 → $90
Current: $62.48
Upside: +44.05%
ProMIS Neurosciences
Feb 6, 2026
Maintains: Buy
Price Target: $125 → $35
Current: $10.39
Upside: +236.86%
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.23
Upside: -
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $21.39
Upside: +49.60%